Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6958688 plus atezolizumab in advanced or metastatic CEA-positive solid tumors
NL-OMON47345Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of cibisatamab and atezolizumab in Nonhematologic neoplasms (2 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicities, Adverse events and infusion-related reactions and 4 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
cibisatamabatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47345.